These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
260 related articles for article (PubMed ID: 31221204)
1. Mechanisms of immune-related adverse events associated with immune checkpoint blockade: using germline genetics to develop a personalized approach. Khan Z; Hammer C; Guardino E; Chandler GS; Albert ML Genome Med; 2019 Jun; 11(1):39. PubMed ID: 31221204 [TBL] [Abstract][Full Text] [Related]
2. Review: Immune-Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer. Suarez-Almazor ME; Kim ST; Abdel-Wahab N; Diab A Arthritis Rheumatol; 2017 Apr; 69(4):687-699. PubMed ID: 28085999 [No Abstract] [Full Text] [Related]
3. ILT4 functions as a potential checkpoint molecule for tumor immunotherapy. Gao A; Sun Y; Peng G Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):278-285. PubMed ID: 29649510 [TBL] [Abstract][Full Text] [Related]
4. Immune-Related Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitors. Sandigursky S; Mor A Curr Rheumatol Rep; 2018 Sep; 20(10):65. PubMed ID: 30191417 [TBL] [Abstract][Full Text] [Related]
5. The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer. van Dijk N; Funt SA; Blank CU; Powles T; Rosenberg JE; van der Heijden MS Eur Urol; 2019 Mar; 75(3):435-444. PubMed ID: 30274701 [TBL] [Abstract][Full Text] [Related]
6. Germline Genetics in Immuno-oncology: From Genome-Wide to Targeted Biomarker Strategies. Kirchhoff T; Ferguson R Methods Mol Biol; 2020; 2055():93-117. PubMed ID: 31502148 [TBL] [Abstract][Full Text] [Related]
11. Exploiting autoimmunity unleashed by low-dose immune checkpoint blockade to treat advanced cancer. Bakacs T; Moss RW; Kleef R; Szasz MA; Anderson CC Scand J Immunol; 2019 Dec; 90(6):e12821. PubMed ID: 31589347 [TBL] [Abstract][Full Text] [Related]
12. Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients? Fares CM; Van Allen EM; Drake CG; Allison JP; Hu-Lieskovan S Am Soc Clin Oncol Educ Book; 2019 Jan; 39():147-164. PubMed ID: 31099674 [TBL] [Abstract][Full Text] [Related]
13. Accelerating the Development of Personalized Cancer Immunotherapy by Integrating Molecular Patients' Profiles with Dynamic Mathematical Models. Agur Z; Elishmereni M; Foryś U; Kogan Y Clin Pharmacol Ther; 2020 Sep; 108(3):515-527. PubMed ID: 32535891 [TBL] [Abstract][Full Text] [Related]
14. Precision Oncology for Cancer Immunotherapies in Early-Phase Clinical Trials. Paliard X; Rixe O Target Oncol; 2019 Dec; 14(6):631-637. PubMed ID: 31595386 [TBL] [Abstract][Full Text] [Related]
15. [Hepatotoxicity associated with tumor immune checkpoint inhibitors]. Lei XH; Tang YY; Li J; Mao YM Zhonghua Gan Zang Bing Za Zhi; 2020 Feb; 28(2):175-178. PubMed ID: 32164073 [TBL] [Abstract][Full Text] [Related]
16. Atypical autoimmune adverse effects with checkpoint blockade therapies. Friedman CF; Snyder A Ann Oncol; 2017 Feb; 28(2):206-207. PubMed ID: 27993802 [No Abstract] [Full Text] [Related]
17. [Checkpoint inhibitors, the perspectives for elderly patients]. Landre T; Karaoud F; Taleb C Soins Gerontol; 2017; 22(127):30-33. PubMed ID: 28917334 [TBL] [Abstract][Full Text] [Related]
18. Adverse events associated with immune checkpoint inhibitor treatment for cancer. Esfahani K; Meti N; Miller WH; Hudson M CMAJ; 2019 Jan; 191(2):E40-E46. PubMed ID: 30642824 [No Abstract] [Full Text] [Related]
19. Cancer immunotherapy: broadening the scope of targetable tumours. van den Bulk J; Verdegaal EM; de Miranda NF Open Biol; 2018 Jun; 8(6):. PubMed ID: 29875199 [TBL] [Abstract][Full Text] [Related]
20. Evolving Paradigms of Personalized Medicine in Oncology. Dhingra K Natl Med J India; 2017; 30(6):305-308. PubMed ID: 30117439 [No Abstract] [Full Text] [Related] [Next] [New Search]